Jump to content

Leucine rich repeat containing 15

From Wikipedia, the free encyclopedia
(Redirected from LRRC15)
LRRC15
Identifiers
AliasesLRRC15, LIB, Leucine rich repeat containing 15
External IDsMGI: 1921738; HomoloGene: 26080; GeneCards: LRRC15; OMA:LRRC15 - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_130830
NM_001135057

NM_028973

RefSeq (protein)

NP_001128529
NP_570843

NP_083249

Location (UCSC)Chr 3: 194.36 – 194.37 MbChr 16: 30.09 – 30.1 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Leucine rich repeat containing 15 is a cell membrane-expressed protein. In humans it is encoded by the LRRC15 [5] gene.[6] It is located on chromosome 3 at 3q29. It belongs to the LRR superfamily, which is involved in cell–cell and cell–ECM interactions.

Preliminary evidence indicates that expression may be related to the severity of COVID-19[7] and that it is an inhibitory accessory factor for SARS-CoV-2 cell entry.[8][9][10][11]

LRRC15 lacks obvious intracellular domains. LRRC15 displays a highly restricted expression pattern, but is expressed in areas that make up innate immune barriers such as the placenta, skin, activated fibroblasts in wounds, and lymphoid tissues such as the spleen.[citation needed]

LRRC15 may play some role in innate immunity.

LRRC15 is aberrantly expressed in cancer. It is highly expressed in CAFs within the stroma of numerous solid tumors and directly expressed in mesenchymal tumors such as glioblastoma, sarcomas, and melanoma.[citation needed]

See also

[edit]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000172061Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000052316Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Reynolds, Paul A.; Smolen, Gromoslaw A.; Palmer, Rachel E.; Sgroi, Dennis; Yajnik, Vijay; Gerald, William L.; Haber, Daniel A. (2003-09-01). "Identification of a DNA-binding site and transcriptional target for the EWS–WT1(+KTS) oncoprotein". Genes & Development. 17 (17): 2094–2107. doi:10.1101/gad.1110703. ISSN 0890-9369. PMC 196452. PMID 12923058.
  6. ^ "Entrez Gene: Leucine rich repeat containing 15".
  7. ^ Gisby JS, Buang NB, Papadaki A, Clarke CL, Malik TH, Medjeral-Thomas N, Pinheiro D, Mortimer PM, Lewis S, Sandhu E, McAdoo SP, Prendecki MF, Willicombe M, Pickering MC, Botto M, Thomas DC, Peters JE (2022). "Multi-omics identify LRRC15 as a COVID-19 severity predictor and persistent pro-1 thrombotic signals in convalescence". medRxiv 10.1101/2022.04.29.22274267v1.
  8. ^ Shilts J, Crozier TM, Teixeira-Silva A, Gabaev I, Greenwood ED, Watson SJ, Ortmann BM, Gawden-Bone CM, Pauzaite T, Hoffmann M, Nathan JA, Pöhlmann S, Lehner PJ, Wright GJ (2021). "LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike protein". bioRxiv 10.1101/2021.09.25.461776.
  9. ^ Song J, Chow RD, Pena-Hernandez M, Zhang L, Loeb SA, So E, Liang OD, Wilen CB, Lee S. "LRRC15 is an inhibitory receptor blocking SARS-CoV-2 spike-mediated entry in trans". bioRxiv 10.1101/2021.11.23.469714.
  10. ^ "Scientists discover receptor that blocks COVID-19 infection". The University of Sydney.
  11. ^ Loo L, Waller MA, Moreno CL, Cole AJ, Stella AO, Pop OT, et al. (February 2023). "Fibroblast-expressed LRRC15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs". PLOS Biology. 21 (2): e3001967. doi:10.1371/journal.pbio.3001967. PMC 9910744. PMID 36757924.

Further reading

[edit]